Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

Share Price is delayed by 15 minutes
Get Live Data
72.80    2.20 (3.13%)
Bid:
71.00
Ask:
74.60
Spread: 3.60 (5.07%)
Market Cap: £91.33m
GCL Live PriceLast checked at - London Stock Exchange

Intraday Geiger Counter Share Chart

Subscription Rights Results 2026

6 May 2026 07:28

RNS Number : 2088D
Geiger Counter Ltd
06 May 2026
 

Geiger Counter Limited (or the "Company")

6 May 2026

Result of subscription rights exercise for Ordinary Shares

 

The Board of the Company announces that applications have been received from shareholders to subscribe for 14,151,839 new ordinary shares of no par value ("Ordinary Shares") at a price of 37.20 pence per share (the "Subscription Price").  A total of 14,151,839 Ordinary Shares will therefore be issued to the successful applicants on the basis of one new Ordinary Share for every five existing Ordinary Shares registered in the name of the successful applicants on the record date, 9 April 2026.

 

Outstanding Subscription Rights

Shareholders did not apply to take up their subscription rights entitlements of 6,815,308 Ordinary Shares. In accordance with the terms and conditions on which the Subscription Rights were issued, the Company has appointed itself as trustee (the "Subscription Trustee"). If the Subscription Trustee is of the opinion that the net proceeds of sale of the Ordinary Shares arising on exercise of the outstanding Subscription Rights (after deduction of all costs and expenses incurred) will exceed the aggregate costs of subscription, the Subscription Trustee will exercise either (i) all the Subscription Rights which have not been exercised or (ii) at the Subscription Trustee's discretion such number of Subscription Rights as will, in the Subscription Trustee's opinion, result in the Ordinary Shares arising from such exercise being sold in the market for such net proceeds as will exceed the costs of exercising such Subscription Share Rights and the costs and expenses of sale.

It is intended that the full number of Ordinary Shares that would arise from the exercise of the outstanding Subscription Rights (the "Rump") will be sold by the Subscription Trustee by way of a secondary market placing executed at the maximum available, single clearing price. However, the Subscription Trustee reserves its absolute discretion to execute bargains in such sizes and prices as it deems appropriate to the interests of the outstanding Subscription Shareholders. Qualified investors (as defined in section 86(7) of the Financial Services and Markets Act 2000 (as amended)) considering participation in the secondary market placing are advised to contact Subscription Trustee as soon as practicable. Orders for the placing should state the number of shares to be purchased and the maximum purchase price (or confirm that the investor is willing to trade "at strike"). Investors placing orders should note that if the full extent of the Rump is not covered, then a bargain is expected to be executed at the maximum available, single clearing price for the actual size of the book. 

If the Subscription Trustee is of the opinion that the gross proceeds of sale of the Ordinary Shares by the Subscription Trustee are likely to exceed the costs of subscription but the excess is not sufficient to meet the costs and expenses incurred by the Subscription Trustee, the Board intends that part or all of such costs and expenses will be borne by the Company, provided that at that time the Board believes this to be in the best interests of the Company and Shareholders as a whole.

The Subscription Trustee will distribute the proceeds of any sale (less any related subscription costs and other costs and expenses) pro rata to the persons entitled thereto, provided that entitlements of under £5.00 shall be retained for the benefit of the Company.

Accordingly, the Company announces that it will be issuing and allotting 14,151,839Ordinary Shares, subject to admission to trading. Application will be made for the new Ordinary Shares to be admitted to trading on the London Stock Exchange. It is expected that dealings will commence at 8.00 a.m. on 11 May 2026.

 

Total Voting Rights

For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), following Admission the issued ordinary share capital of the Company will consist of 166,826,088 Ordinary Shares, of which 47,838,208 shares are held in treasury by the Company, resulting in 118,987,880 Ordinary Shares with voting rights attached. This figure of 118,987,880 may be used by the Company's shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the DTRs.

All shareholders will have a further right to subscribe for shares on 30 April 2027 (on the basis of one new Ordinary Share for every five Ordinary Shares held). The subscription price will be equal to the unaudited diluted net asset value per share on 1 May 2026. A reminder will be sent to shareholders prior to the next subscription date.

 

Enquiries

 

Manulife | CQS Investment Management 

Craig Cleland

T: +44 (0) 20 7201 5368

Cavendish Capital Markets Limited

Tunga Chigovanyika

 (Corporate Finance)

T: +44 (0) 20 7397 1915

Daniel Balabanoff / Pauline Tribe (Sales)

T: +44 (0) 20 7220 0500

Summit Fund Services Jersey Limited

Christopher Foulds

T:+44 (0) 1534 825 259

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROIAFMFTMTTMMFF
Date   Source Headline
3rd Jun 202612:22 pmRNSNet Asset Value(s)
2nd Jun 20262:04 pmRNSAppointment of Non-Executive Director
2nd Jun 20261:23 pmRNSNet Asset Value(s)
1st Jun 202612:24 pmRNSNet Asset Value(s)
29th May 20261:30 pmRNSNet Asset Value(s)
28th May 20263:31 pmRNSNet Asset Value(s)
27th May 20264:23 pmRNSNet Asset Value(s)
27th May 202611:57 amRNSMonthly Factsheet - April 2026
26th May 20265:24 pmRNSNet Asset Value(s)
22nd May 20262:06 pmRNSNet Asset Value(s)
21st May 20261:09 pmRNSNet Asset Value(s)
20th May 20263:20 pmRNSNet Asset Value(s)
19th May 20263:08 pmRNSNet Asset Value(s)
18th May 20261:36 pmRNSNet Asset Value(s)
15th May 20264:29 pmRNSPortfolio Management Update
15th May 20262:08 pmRNSNet Asset Value(s)
15th May 202612:42 pmRNSDistribution of Rump proceeds
14th May 20262:50 pmRNSNet Asset Value(s)
13th May 20262:19 pmRNSNet Asset Value(s)
13th May 20261:50 pmRNSHolding(s) in Company
12th May 20263:56 pmRNSHolding(s) in Company
12th May 20263:35 pmRNSDirector/PDMR Shareholding
12th May 20263:28 pmRNSNet Asset Value(s)
11th May 20262:45 pmRNSNet Asset Value(s)
8th May 20263:20 pmRNSNet Asset Value(s)
7th May 20264:28 pmRNSNet Asset Value(s)
7th May 20268:55 amRNSSubscription Rights Rump Placing
6th May 20265:19 pmRNSNet Asset Value(s)
6th May 20267:40 amRNSSubscription Rights for 2027
6th May 20267:28 amRNSSubscription Rights Results 2026
5th May 20264:50 pmRNSNet Asset Value(s)
1st May 20263:14 pmRNSNet Asset Value(s)
30th Apr 20264:08 pmRNSNet Asset Value(s)
29th Apr 20263:00 pmRNSNet Asset Value(s)
28th Apr 20262:52 pmRNSNet Asset Value(s)
28th Apr 202610:10 amRNS-RUpdate research from QuotedData
27th Apr 20262:55 pmRNSNet Asset Value(s)
24th Apr 20262:58 pmRNSNet Asset Value(s)
23rd Apr 20262:55 pmRNSNet Asset Value(s)
23rd Apr 202610:09 amRNSMonthly Factsheet- March 2026
22nd Apr 20261:38 pmRNSNet Asset Value(s)
21st Apr 20262:55 pmRNSNet Asset Value(s)
20th Apr 202612:20 pmRNSNet Asset Value(s)
17th Apr 20263:29 pmRNSNet Asset Value(s)
16th Apr 20262:35 pmRNSNet Asset Value(s)
16th Apr 202610:41 amRNSDirectors intent re subscription rights
15th Apr 20261:29 pmRNSNet Asset Value(s)
14th Apr 20261:11 pmRNSNet Asset Value(s)
14th Apr 20267:52 amRNSNet Asset Value(s)
10th Apr 20261:55 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.